Turkish Thoracic Journal
Review

Anti-IL-5 Biologicals Targeting Severe Late Onset Eosinophilic Asthma

1.

Department of Pulmonary Disease, Division of Immunology and Allergy, Koc University, School of Medicine, Istanbul, Turkey

2.

Department of Pulmonary Disease, Division of Immunology and Allergy, School of Medicine, Ankara University, Ankara, Turkey

Turk Thorac J 2020; 21: 61-68
DOI: 10.5152/TurkThoracJ.2019.180204
Read: 339 Downloads: 133 Published: 13 September 2019

Improved knowledge about the pathogenesis of asthma has facilitated the development of novel drugs and provided hope for patients with severe asthma. After the short- and long-term success of omalizumab in severe allergic phenotype, researchers have targeted patients with severe eosinophilic asthma who comprise up to 45% of adult severe asthma. Interleukin (IL)-5 and IL-5 receptor subunit α play crucial roles in the development, maturation, and operation of eosinophils. Currently, patients treated with anti-IL-5 biologicals depleting eosinophils experience the positive efficacy of these drugs, especially with regard to the reduction of exacerbation rate. The aim of this review was to shed light on severe eosinophilic asthma treatment with these new currently available agents selectively targeting IL-5 or its receptor, discussing their usage including pre-treatment concerns, such as selecting the target population and choosing the right agent among them, and subsequent assessment of relevant effect and safety issues.

Cite this article as: Pur Özyiğit L, Öztürk AB, Bavbek S. Anti-IL-5 Anti-IL-5 Biologicals Targeting Severe Late Onset Eosinophilic Asthma. Turk Thorac J 2020; 21(1): 61-8.

Files
EISSN 2149-2530